Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H33N3O9S2 |
| Molecular Weight | 619.706 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC(=O)COC1=C(CCNS(=O)(=O)C2=CC(=CC=C2O)C(=N)NO)C=CC(=C1)C3=C(C=CC=C3)S(C)(=O)=O
InChI
InChIKey=PQCIYLDSCOZTFR-UHFFFAOYSA-N
InChI=1S/C28H33N3O9S2/c1-3-4-15-39-27(33)18-40-24-16-20(22-7-5-6-8-25(22)41(2,35)36)10-9-19(24)13-14-30-42(37,38)26-17-21(28(29)31-34)11-12-23(26)32/h5-12,16-17,30,32,34H,3-4,13-15,18H2,1-2H3,(H2,29,31)
| Molecular Formula | C28H33N3O9S2 |
| Molecular Weight | 619.706 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:47:27 GMT 2023
by
admin
on
Sat Dec 16 11:47:27 GMT 2023
|
| Record UNII |
GCY242SXH4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
763076-29-5
Created by
admin on Sat Dec 16 11:47:27 GMT 2023 , Edited by admin on Sat Dec 16 11:47:27 GMT 2023
|
PRIMARY | |||
|
GCY242SXH4
Created by
admin on Sat Dec 16 11:47:27 GMT 2023 , Edited by admin on Sat Dec 16 11:47:27 GMT 2023
|
PRIMARY | |||
|
135443382
Created by
admin on Sat Dec 16 11:47:27 GMT 2023 , Edited by admin on Sat Dec 16 11:47:27 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Many polymorphs of KFA-1982, an orally active factor Xa (fXa) inhibitor, have been identified and their physicochemical properties have been investigated. Form B was selected as the oral API form because of its superior stability and solubility characteristics. The hydrochloride salt was selected for the API because of good stability.
|
||
|
ACTIVE MOIETY |
Class: Antithrombotic; Mechanism of Action: Factor Xa inhibitor; Highest Development Phase: Phase I Deep vein thrombosis, Thrombosis: Most Recent Events: 01 Oct 2003 Phase-I clinical trials in Thrombosis in Japan (PO), 01 Oct 2003 Phase-I clinical trials in Thrombosis in Europe (PO)
|
